BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 29042174)

  • 21. Children and adolescents with marginal zone lymphoma have an excellent prognosis with limited chemotherapy or a watch-and-wait strategy after complete resection.
    Ronceray L; Abla O; Barzilai-Birenboim S; Bomken S; Chiang AK; Jazbec J; Kabickova E; Lazic J; Beishuizen A; Mellgren K; Tanaka F; Pillon M; Devalck C; Gouttenoire M; Makarova O; Burkhardt B; Attarbaschi A;
    Pediatr Blood Cancer; 2018 Apr; 65(4):. PubMed ID: 29286565
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The many faces of marginal zone lymphoma.
    Zinzani PL
    Hematology Am Soc Hematol Educ Program; 2012; 2012():426-32. PubMed ID: 23233614
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term treatment of localized gastric marginal zone B-cell mucosa associated lymphoid tissue lymphoma including incidence of metachronous gastric cancer.
    Ono S; Kato M; Takagi K; Kodaira J; Kubota K; Matsuno Y; Komatsu Y; Asaka M
    J Gastroenterol Hepatol; 2010 Apr; 25(4):804-9. PubMed ID: 20492338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).
    Kiesewetter B; Mayerhoefer ME; Lukas J; Zielinski CC; Müllauer L; Raderer M
    Ann Hematol; 2014 Feb; 93(2):249-53. PubMed ID: 23925930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma.
    Teckie S; Qi S; Chelius M; Lovie S; Hsu M; Noy A; Portlock C; Yahalom J
    Ann Oncol; 2017 May; 28(5):1064-1069. PubMed ID: 28327924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term efficacy and toxicity of rituximab plus fludarabine and mitoxantrone (R-FM) for gastric marginal zone lymphoma: a single-center experience and literature review.
    Cencini E; Fabbri A; Lauria F; Bocchia M
    Ann Hematol; 2018 May; 97(5):821-829. PubMed ID: 29340761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.
    Karmali R; Kassar M; Venugopal P; Shammo JM; Fung HC; Bayer R; O'Brien T; Gregory SA
    Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):467-74. PubMed ID: 21700527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extranodal marginal zone B-cell lymphoma most probably of MALT type appearing in CNS as parasagittal extracerebral tumor.
    Marinković M; Slavik E; Janković S; Cemerikic V; Radulović D
    J Neurosurg Sci; 2006 Mar; 50(1):9-12. PubMed ID: 16557194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma.
    Orciuolo E; Buda G; Sordi E; Baraté C; Galimberti S; Ciancia E; Petrini M
    Leuk Res; 2010 Feb; 34(2):184-9. PubMed ID: 19414190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Primary MALT-type lymphoma of the breast].
    Rafel M; Esteve J; Cervantes F; Velasco M; Serra A; Campo E; Montserrat E
    Sangre (Barc); 1998 Jun; 43(3):244-7. PubMed ID: 9741235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk adapted approach: How to treat splenic marginal zone lymphoma in resource-poor settings? - The real-life experience of a Brazilian cancer treatment center.
    de Pádua Covas Lage LA; Dos Santos FFC; Levy D; Moreira FR; Couto SCF; Culler HF; de Oliveira Costa R; Rocha V; Pereira J
    BMC Cancer; 2020 Aug; 20(1):717. PubMed ID: 32746790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab.
    Bennett M; Schechter GP
    Semin Hematol; 2010 Apr; 47(2):143-7. PubMed ID: 20350661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome.
    Tsang RW; Gospodarowicz MK; Pintilie M; Wells W; Hodgson DC; Sun A; Crump M; Patterson BJ
    J Clin Oncol; 2003 Nov; 21(22):4157-64. PubMed ID: 14615444
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas.
    Castelli R; Bergamaschini L; Deliliers GL
    Med Oncol; 2017 Dec; 35(2):15. PubMed ID: 29288421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Waldeyer's ring marginal zone B cell lymphoma: are the clinical and prognostic features nodal or extranodal? A study by the Consortium for Improving Survival of Lymphoma (CISL).
    Oh SY; Kim WS; Kim JS; Kim SJ; Lee S; Lee DH; Lee SI; Kang HJ; Choi CW; Park J; Song MK; Kim HJ; Kwon JH; Kwak JY; Bae SH; Park BB; Do YR; Lee HS; Jeong SH; Suh C; Kim HJ
    Int J Hematol; 2012 Nov; 96(5):631-7. PubMed ID: 23065471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Marginal Zone Lymphoma: State-of-the-Art Treatment.
    Sindel A; Al-Juhaishi T; Yazbeck V
    Curr Treat Options Oncol; 2019 Dec; 20(12):90. PubMed ID: 31807935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Floral leukemic cells transformed from marginal zone lymphoma.
    Chang ST; Hsieh YC; Lu YH; Tzeng CC; Lin CN; Chuang SS
    Pathol Res Pract; 2008; 204(1):23-6. PubMed ID: 17913385
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy.
    Rosenthal A; Dueck AC; Ansell S; Gano K; Conley C; Nowakowski GS; Camoriano J; Leis JF; Mikhael JR; Keith Stewart A; Inwards D; Dingli D; Kumar S; Noel P; Gertz M; Porrata L; Russell S; Colgan J; Fonseca R; Habermann TM; Kapoor P; Buadi F; Leung N; Tiedemann R; Witzig TE; Reeder C
    Am J Hematol; 2017 May; 92(5):467-472. PubMed ID: 28230270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients.
    Boveri E; Arcaini L; Merli M; Passamonti F; Rizzi S; Vanelli L; Rumi E; Rattotti S; Lucioni M; Picone C; Castello A; Pascutto C; Magrini U; Lazzarino M; Paulli M
    Ann Oncol; 2009 Jan; 20(1):129-36. PubMed ID: 18718888
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas.
    Brown JR; Friedberg JW; Feng Y; Scofield S; Phillips K; Dal Cin P; Joyce R; Takvorian RW; Fisher DC; Fisher RI; Liesveld J; Marquis D; Neuberg D; Freedman AS
    Br J Haematol; 2009 Jun; 145(6):741-8. PubMed ID: 19344412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.